These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


167 related items for PubMed ID: 2687007

  • 21. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
    Hillman RJ, Scott M, Gray RS.
    Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
    [Abstract] [Full Text] [Related]

  • 22. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ, Spencer CM.
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [Abstract] [Full Text] [Related]

  • 23. Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol.
    Lembcke B, Diederich M, Fölsch UR, Creutzfeldt W.
    Digestion; 1990 Mar; 47(1):47-55. PubMed ID: 2292349
    [Abstract] [Full Text] [Related]

  • 24. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
    Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M, Rossi CM.
    Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
    [Abstract] [Full Text] [Related]

  • 25. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
    Russell JC, Graham SE, Dolphin PJ.
    Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143
    [Abstract] [Full Text] [Related]

  • 26. The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
    Hillebrand I, Boehme K, Graefe KH, Wehling K.
    Klin Wochenschr; 1986 Apr 15; 64(8):393-6. PubMed ID: 3517475
    [Abstract] [Full Text] [Related]

  • 27. Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
    Dimitriadis G, Hatziagellaki E, Alexopoulos E, Kordonouri O, Komesidou V, Ganotakis M, Raptis S.
    Diabetes Care; 1991 May 15; 14(5):393-8. PubMed ID: 2060451
    [Abstract] [Full Text] [Related]

  • 28. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
    Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P.
    Diabetes Obes Metab; 2001 Oct 15; 3(5):326-31. PubMed ID: 11703422
    [Abstract] [Full Text] [Related]

  • 29. Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet.
    Madar Z.
    Am J Clin Nutr; 1989 Jan 15; 49(1):106-11. PubMed ID: 2643291
    [Abstract] [Full Text] [Related]

  • 30. Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
    Joubert PH, Bam WJ, Manyane N.
    Eur J Clin Pharmacol; 1986 Jan 15; 30(2):253-5. PubMed ID: 3519244
    [Abstract] [Full Text] [Related]

  • 31. Effect of miglitol administration to non-insulin-dependent diabetic rats.
    Tormo MA, Ropero MF, Nieto M, Martinez IM, Campillo JE.
    Gen Pharmacol; 1998 Jan 15; 30(1):125-9. PubMed ID: 9457493
    [Abstract] [Full Text] [Related]

  • 32. The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
    Kennedy FP, Miles JM, Heiling V, Gerich JE.
    Clin Exp Pharmacol Physiol; 1987 Aug 15; 14(8):633-40. PubMed ID: 3326689
    [Abstract] [Full Text] [Related]

  • 33. Effect of miglitol and acarbose on starch digestion, daily plasma glucose profiles and cataract formation.
    Madar Z, Hazan A.
    J Basic Clin Physiol Pharmacol; 1993 Aug 15; 4(1-2):69-81. PubMed ID: 8679512
    [Abstract] [Full Text] [Related]

  • 34. The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
    DeBouno JF, Michaelis OE, Tulp OL.
    Gen Pharmacol; 1993 Mar 15; 24(2):509-15. PubMed ID: 8482529
    [Abstract] [Full Text] [Related]

  • 35. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
    Campbell LK, Baker DE, Campbell RK.
    Ann Pharmacother; 2000 Nov 15; 34(11):1291-301. PubMed ID: 11098345
    [Abstract] [Full Text] [Related]

  • 36. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
    Holman RR, Steemson J, Turner RC.
    Diabetes Res; 1991 Dec 15; 18(4):149-53. PubMed ID: 1842749
    [Abstract] [Full Text] [Related]

  • 37. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
    Madar Z.
    J Nutr; 1989 Dec 15; 119(12):2023-9. PubMed ID: 2695605
    [Abstract] [Full Text] [Related]

  • 38. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
    Aoki K, Kato H, Terauchi Y.
    Endocr J; 2007 Dec 15; 54(6):1009-14. PubMed ID: 18048991
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
    Samad AH, Ty Willing TS, Alberti KG, Taylor R.
    Diabetes Care; 1988 Apr 15; 11(4):337-44. PubMed ID: 3042310
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 9.